- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.06. | BioAdaptives Inc.: BioAdaptives Announces National Launch of Pawpa Regen | 3 | GlobeNewswire (USA) | ||
| 28.05. | BioAdaptives Inc.: BioAdaptives PawPa Regen Provides Breakthrough Stem Cell Support for Pets, Backed by Clinically Proven APBAR Scale Improvements | 1 | GlobeNewswire (USA) | ||
| 13.05. | BIOADAPTIVES, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 15.04. | BIOADAPTIVES, INC. - 10-K, Annual Report | 1 | SEC Filings | ||
| 31.03. | BIOADAPTIVES, INC. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | 1 | SEC Filings | ||
| 13.03. | BioAdaptives Inc.: Zeranovia Weight Loss Product Shows Promising Results in Dosage Trial | 115 | GlobeNewswire (Europe) | LAS VEGAS, March 13, 2025 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives Inc. (OTC: BDPT) today announced the successful completion of dosage trials for its innovative weight loss product, Zeranovia.... ► Artikel lesen | |
| BIOADAPTIVES Aktie jetzt für 0€ handeln | |||||
| 07.02. | BIOADAPTIVES, INC. - 8-K, Current Report | - | SEC Filings | ||
| 06.02. | BioAdaptives Inc.: BioAdaptives Welcomes UFC Senior Executive Reed Harris to Its Board of Advisors | 2 | GlobeNewswire (USA) | ||
| 03.02. | BioAdaptives Inc.: BioAdaptives Welcomes Mark Frissora, Acclaimed Business Leader, to Its Board of Directors | 1 | GlobeNewswire (USA) | ||
| 25.11.24 | BioAdaptives Inc.: BioAdaptives, Inc. Announces Institutional Review Board Approval of a Human Clinical Trial for Zeranovia | 128 | GlobeNewswire (Europe) | LAS VEGAS, Nov. 25, 2024 (GLOBE NEWSWIRE) -- via IBN - BioAdaptives Inc. (OTC: BDPT) received approval today for a human clinical trial of its weight management product, Zeranovia. The trial, approved... ► Artikel lesen | |
| 13.11.24 | BioAdaptives Inc.: BioAdaptives, Inc. Announces Complete Product Overhaul with New Line of Scientifically Advanced Solutions | 110 | GlobeNewswire (Europe) | LAS VEGAS, Nov. 13, 2024 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives, Inc. (OTC: BDPT), a leading provider of innovative nutritional products, announces today a transformative shift in its product... ► Artikel lesen | |
| 29.10.24 | BioAdaptives Inc.: BioAdaptives, Inc. Letter to Shareholders Regarding the Reverse Stock Split | 90 | GlobeNewswire (Europe) | LAS VEGAS, Oct. 29, 2024 (GLOBE NEWSWIRE) -- via IBN -- Due to a website maintenance error, a draft of a letter to BioAdaptives® (OTC: BDPT) shareholders was made available on the BioAdaptives® website.... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| RECURSION PHARMACEUTICALS | 6,380 | 0,00 % | Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? | ||
| ITEOS THERAPEUTICS | 10,135 | 0,00 % | iTeos Therapeutics Inc.: iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right | WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. ("iTeos") (Nasdaq: ITOS) today announced that it has entered into a definitive merger agreement... ► Artikel lesen | |
| EVOTEC | 6,218 | -16,60 % | Evotec-Aktie mit Kursgewinnen (7,346 €) | Im Plus liegt derzeit der Anteilsschein von Evotec . Das Papier kostete zuletzt 7,35 Euro. Heute hat sich am deutschen Aktienmarkt das Wertpapier von Evotec zwischenzeitlich um 3,41 Prozent verteuert.... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 34,040 | +0,83 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants | -- Unprecedented data from FORTITUDE dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,020 | 0,00 % | Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress | Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Patients... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 26,340 | +0,53 % | Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings | ||
| SAB BIOTHERAPEUTICS | 2,655 | 0,00 % | SAB Biotherapeutics: Oppenheimer erhöht Kursziel auf 14 US-Dollar | ||
| REDHILL BIOPHARMA | 2,380 | 0,00 % | RedHill Biopharma Ltd.: RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease | The positive FDA feedback allows for:
A novel Phase 2 RHB-204[1] study, planned to be the first ever clinical study in a specifically defined Mycobacterium avium... ► Artikel lesen | |
| 180 LIFE SCIENCES | 2,800 | 0,00 % | 180 Life Sciences Corp. Announces Strengthening of Legacy Intellectual Property Assets | PALO ALTO, CA / ACCESS Newswire / July 1, 2025 / 180 Life Sciences Corp. (NASDAQ:ATNF) ("180" or the "Company), an innovative biotechnology company that is currently pivoting to the global iGaming sector... ► Artikel lesen | |
| ABSCI | 3,505 | 0,00 % | Absci Corporation: Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease | Absci becomes clinical stage company with ABS-101, first AI-designed biologic for IBD, beginning Phase 1 trial Preclinical data for ABS-101 demonstrates high potency and potential for quarterly dosing... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,130 | +2,39 % | ADMA Biologics, Inc.: ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update | 1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 35,210 | +0,03 % | Truist Securities initiates Harmony Biosciences stock with Buy rating | ||
| KYMERA THERAPEUTICS | 45,140 | 0,00 % | Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock? | ||
| VERVE THERAPEUTICS | 10,955 | +0,37 % | Verve Therapeutics sichert Führungskräfte mit Halteprämien vor Übernahme durch Eli Lilly | ||
| SANA BIOTECHNOLOGY | 4,450 | 0,00 % | Sana Biotechnology, Inc: Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression | Groundbreaking First-in-Human Study Establishes Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression Six-Month Patient Follow-up Results Demonstrate... ► Artikel lesen |
BIOADAPTIVES INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOADAPTIVES INC finden Sie auf Wallstreet Online.